Hangzhou Ruipu Chenchuang Technology

Hangzhou Ruipu Chenchuang Technology (Reprogenix Bioscience) is a Chinese biotechnology company specializing in regenerative medicine and stem cell therapies. Founded in 2014 by Dr. Lieming Ding and Professor Hongkui Deng, the company focuses on developing innovative treatments for diabetes using induced pluripotent stem cell (iPSC) technology. Its lead program, RGB-5088, is an autologous iPSC-derived islet cell therapy for Type 1 diabetes that has received IND approval for Phase 1 clinical trials in China. Reprogenix utilizes a proprietary platform encompassing chemically induced pluripotent stem cell (CiPSC) reprogramming and AI-powered differentiation technologies. The company is backed by prominent investors including Betta Pharmaceuticals and Lotus Lake Capital, and recently closed a significant Series A+ financing round to advance its clinical pipeline.